Cellarity
Avak Kahvejian is a board member at Cellarity. Avak has also previously served on the boards of Laronde, Generate Biomedicines, Inc., Cygnal Therapeutics, Ring Therapeutics, Codiak BioSciences, Rubius Therapeutics, and Flagship Pioneering. In addition to their board work, Kahvejian was the founding team's vice president of business development at Liberate Diagnostics where they developed the company's business plan and established partnerships with breast cancer Centers of Excellence to launch myBRCAscan(TM), the first alternative BRCA1/2 sequencing test at the time.
Avak Kahvejian has a Ph.D. in Biochemistry from McGill University. Avak also holds a B.Sc. in Biochemistry with Honors from McGill University, and a DEC in General Sciences from Marianopolis College. Avak is a graduate of Collège Stanislas, where they completed their DES (High School) studies.
This person is not in the org chart
Cellarity
1 followers
Founded by Flagship Pioneering, Cellarity is the first company developing medicines through an understanding of cell behaviors. The company’s broad platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them.